长期质子泵抑制剂对磷钙代谢和骨密度的影响。
Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.
作者信息
Smaoui Hend, Chtourou Lassaad, Jallouli Dana, Jemaa Samar Ben, Karaa Iheb, Boudabbous Mouna, Moalla Manel, Gdoura Hela, Mnif Leila, Amouri Ali, Akrout Rim, Ayadi Fatma, Baklouti Sofien, Tahri Nabil
机构信息
Department of Gastroenterology & Hepatology, Hedi Chaker University Hospital, Sfax, Tunisia.
Laboratory of Biochemistry, Habib Bourguiba University Hospital, Sfax, Tunisia.
出版信息
Future Sci OA. 2024 May 24;10(1):FSO977. doi: 10.2144/fsoa-2023-0198. eCollection 2024.
Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass. This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment. A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent. Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.
尽管质子泵抑制剂（PPIs）耐受性良好，但其长期使用可能与骨量减少有关。这是一项病例对照研究，纳入了接受PPIs治疗（>1年）的患者以及未接受PPIs治疗的对照受试者。共纳入90例患者和90例匹配的对照。使用PPIs与低钙血症和低镁血症有关。维生素D3缺乏和甲状旁腺功能亢进与使用PPIs有关。长期使用PPIs与骨密度降低显著相关。骨矿物质密度（BMD）降低的危险因素包括年龄>50岁、绝经、缺乏阳光照射、双倍PPIs剂量、每日摄入量、餐后摄入以及与黏膜保护剂联用。我们的结果凸显了长期接受PPIs治疗的患者发生BMD降低的风险。
Zotero 插件